Annual Meeting to be held May 23, 2024
PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc.
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company focused on developing and commercializing
products to treat rare diseases where there is an unmet medical
need, encourages its eligible stockholders to participate in the
upcoming Annual Meeting of Stockholders to be held virtually at
9:00AM ET on May 23, 2024. "This Annual Meeting is exceedingly
important to the Company," stated Christopher J. Schaber, PhD, President and Chief
Executive Officer of Soligenix. "We have a number of proposals to
be voted on in order to continue to provide value to our
stockholders and advance our rare disease pipeline forward,
including our confirmatory Phase 3 study with HyBryte™
for the treatment of cutaneous T-cell lymphoma (CTCL)."
Only stockholders at the close of business on the record date,
April 10, 2024, will be eligible to
participate. Even stockholders as of April
10, 2024 who have subsequently sold their shares are
eligible and encouraged to vote. While voting via the Internet and
by phone before the meeting will be open until May 22, 2024 at 11:59 PM
ET, we encourage eligible stockholders to vote as early as
possible to ensure their vote is counted.
Eligible stockholders may vote their shares via the Internet,
telephone or mail:
- Go to www.proxyvote.com and follow the instructions (have your
proxy card available)
- Call 1-800-690-6903 and follow the voice prompts (have your
proxy card available)
- If you have received a proxy card, mark your vote, sign your
name exactly as it appears on your proxy card, date your card and
return it in the envelope provided
Please refer to the official proxy filing for further details on
each proposal, this can be found at
https://ir.soligenix.com/sec-filings.
About Soligenix
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing and moving toward
potential commercialization of HyBryte™ (SGX301 or
synthetic hypericin sodium) as a novel photodynamic therapy
utilizing safe visible light for the treatment of cutaneous T-cell
lymphoma (CTCL). With successful completion of the second Phase 3
study, regulatory approvals will be sought to support potential
commercialization worldwide. Development programs in this business
segment also include expansion of synthetic hypericin (SGX302) into
psoriasis, our first-in-class innate defense regulator (IDR)
technology, dusquetide (SGX942) for the treatment of inflammatory
diseases, including oral mucositis in head and neck cancer, and
(SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes
development programs for RiVax®, our ricin toxin vaccine
candidate, as well as our vaccine programs targeting filoviruses
(such as Marburg and Ebola) and CiVax™, our vaccine
candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
The development of our vaccine programs incorporates the use of our
proprietary heat stabilization platform technology, known as
ThermoVax®. To date, this business segment has been
supported with government grant and contract funding from the
National Institute of Allergy and Infectious Diseases (NIAID), the
Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced
Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at https://www.soligenix.com and
follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that
reflect Soligenix's current expectations about its future results,
performance, prospects and opportunities, including but not limited
to, potential market sizes, patient populations, clinical trial
enrollment, the expected timing for closing the offering described
herein and the intended use of proceeds therefrom. Statements that
are not historical facts, such as "anticipates," "estimates,"
"believes," "hopes," "intends," "plans," "expects," "goal," "may,"
"suggest," "will," "potential," or similar expressions, are
forward-looking statements. These statements are subject to a
number of risks, uncertainties and other factors that could cause
actual events or results in future periods to differ materially
from what is expressed in, or implied by, these statements, and
include the expected amount and use of proceeds from the offering
and the expected closing date of the offering. Soligenix cannot
assure you that it will be able to successfully develop, achieve
regulatory approval for or commercialize products based on its
technologies, particularly in light of the significant uncertainty
inherent in developing therapeutics and vaccines against bioterror
threats, conducting preclinical and clinical trials of therapeutics
and vaccines, obtaining regulatory approvals and manufacturing
therapeutics and vaccines, that product development and
commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further funding to
support product development and commercialization efforts,
including grants and awards, maintain its existing grants which are
subject to performance requirements, enter into any biodefense
procurement contracts with the U.S. Government or other countries,
that it will be able to compete with larger and better financed
competitors in the biotechnology industry, that changes in health
care practice, third party reimbursement limitations and Federal
and/or state health care reform initiatives will not negatively
affect its business, or that the U.S. Congress may not pass any
legislation that would provide additional funding for the Project
BioShield program. In addition, there can be no assurance as to the
timing or success of any of its clinical/preclinical trials.
Despite the statistically significant result achieved in the first
HyBryte™ (SGX301) Phase 3 clinical trial for the
treatment of cutaneous T-cell lymphoma, there can be no assurance
that the second HyBryte™ (SGX301) Phase 3 clinical trial
will be successful or that a marketing authorization from the FDA
or EMA will be granted. Additionally, although the EMA has agreed
to the key design components of the second HyBryte™
(SGX301) Phase 3 clinical trial, no assurance can be given that the
Company will be able to modify the development path to adequately
address the FDA's concerns or that the FDA will not require a
longer duration comparative study. Notwithstanding the result
in the first HyBryte™ (SGX301) Phase 3 clinical trial
for the treatment of cutaneous T-cell lymphoma and the Phase 2a
clinical trial of SGX302 for the treatment of psoriasis, there can
be no assurance as to the timing or success of the clinical trials
of SGX302 for the treatment of psoriasis. Further, there can be no
assurance that RiVax® will qualify for a biodefense
Priority Review Voucher (PRV) or that the prior sales of PRVs will
be indicative of any potential sales price for a PRV for
RiVax®. Also, no assurance can be provided that the
Company will receive or continue to receive non-dilutive government
funding from grants and contracts that have been or may be awarded
or for which the Company will apply in the future. These and other
risk factors are described from time to time in filings with the
Securities and Exchange Commission (the "SEC"), including, but not
limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless
required by law, Soligenix assumes no obligation to update or
revise any forward-looking statements as a result of new
information or future events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/soligenix-encourages-stockholders-to-vote-prior-to-annual-meeting-302149438.html
SOURCE SOLIGENIX, INC.
